Los fundamentos de la empresa son relativamente saludable. Su valoración está considerada valorada de forma justa,y su reconocimiento institucional es muy alto. En los últimos 30 días, múltiples analistas han calificado a la empresa como Compra. Pese a que su rendimiento bursátil es débil, la empresa muestra unos fundamentos sólidos. Las acciones se mantienen sin una tendencia clara entre los niveles de soporte y resistencia, así que son adecuadas para el swing trading en un mercado lateral.
Puntuación de acciones
Información Relacionada
Ranking de la industria
101 / 175
Clasificación general
337 / 4720
Industria
Productos farmacéuticos
Resistencia y Soporte
Sin datos
Gráfico de radar
Precio actual
Anterior
Objetivo de los analistas
Basado en un total de
1
analistas
Compra
Calificación actual
2.000
Precio objetivo
+177.93%
Espacio en ascenso
Descargo de responsabilidad: Las calificaciones de los analistas y los precios objetivo son proporcionados por LSEG con fines informativos únicamente y no constituyen asesoramiento de inversión.
Aspectos destacados de la empresa
Puntos fuertesRiesgo
cbdMD, Inc. is a cannabidiol (CBD) company. The Company has a comprehensive line of United States produced, THC-free CBD products, including NSF Certified for Sport products, as well as its new Full Spectrum products. The Company's flagship brands include cbdMD and Paw CBD, as well as its functional mushroom brand ATRx Labs. Its cbdMD brand includes high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD sleep aids and CBD drink products including its Herbal Oasis Social Tonic and an array of Farm Act compliant Delta 9 products. Its Paw CBD brand of pet products includes veterinarian-formulated products including tinctures, chews, topicals products in varying strengths, and its ATRx brand of natural functional mushroom support. Its cbdMD, Paw CBD and ATRx products are distributed through its e-commerce websites, third party e-commerce sites, select distributors and marketing partners as well as a variety of brick-and-mortar retailers.
Creciendo
La empresa se encuentra en una fase de crecimiento. Sus ingresos anuales más recientes ascienden a 19.48M USD.
Sobrevalorada
El PE más reciente de la empresa es -0.44, en un rango percentil alto de 3 años.
Compra institucional
Las tenencias institucionales más recientes son 1.71M acciones, lo que supone un aumento del 47.57% con respecto al trimestre anterior.
Mayor actividad del mercado
La empresa está generando mayor interés entre los inversores, con una relación de rotación de 20 días del -0.27.
cbdMD, Inc. is a cannabidiol (CBD) company. The Company has a comprehensive line of United States produced, THC-free CBD products, including NSF Certified for Sport products, as well as its new Full Spectrum products. The Company's flagship brands include cbdMD and Paw CBD, as well as its functional mushroom brand ATRx Labs. Its cbdMD brand includes high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD sleep aids and CBD drink products including its Herbal Oasis Social Tonic and an array of Farm Act compliant Delta 9 products. Its Paw CBD brand of pet products includes veterinarian-formulated products including tinctures, chews, topicals products in varying strengths, and its ATRx brand of natural functional mushroom support. Its cbdMD, Paw CBD and ATRx products are distributed through its e-commerce websites, third party e-commerce sites, select distributors and marketing partners as well as a variety of brick-and-mortar retailers.